Francesco Autore, Andrea Visentin, Marina Deodato, Candida Vitale, Eugenio Galli, Alberto Fresa, Rita Fazzi, Alessandro Sanna, Jacopo Olivieri, Ilaria Scortechini, Maria Ilaria Del Principe, Paolo Sportoletti, Idanna Innocenti, Marta Coscia, Alessandra Tedeschi, Livio Trentin, Anna Candoni, Alessandro Busca, Livio Pagano, Luca Laurenti
{"title":"接受 Venetoclax 治疗的慢性淋巴细胞白血病患者的 COVID-19:抗 CD20 抗体的作用是什么?","authors":"Francesco Autore, Andrea Visentin, Marina Deodato, Candida Vitale, Eugenio Galli, Alberto Fresa, Rita Fazzi, Alessandro Sanna, Jacopo Olivieri, Ilaria Scortechini, Maria Ilaria Del Principe, Paolo Sportoletti, Idanna Innocenti, Marta Coscia, Alessandra Tedeschi, Livio Trentin, Anna Candoni, Alessandro Busca, Livio Pagano, Luca Laurenti","doi":"10.1182/bloodadvances.2024013792","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":null,"pages":null},"PeriodicalIF":7.4000,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: what is the role of anti-CD20 antibody?\",\"authors\":\"Francesco Autore, Andrea Visentin, Marina Deodato, Candida Vitale, Eugenio Galli, Alberto Fresa, Rita Fazzi, Alessandro Sanna, Jacopo Olivieri, Ilaria Scortechini, Maria Ilaria Del Principe, Paolo Sportoletti, Idanna Innocenti, Marta Coscia, Alessandra Tedeschi, Livio Trentin, Anna Candoni, Alessandro Busca, Livio Pagano, Luca Laurenti\",\"doi\":\"10.1182/bloodadvances.2024013792\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9228,\"journal\":{\"name\":\"Blood advances\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.4000,\"publicationDate\":\"2024-10-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood advances\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1182/bloodadvances.2024013792\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood advances","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/bloodadvances.2024013792","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
期刊介绍:
Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016.
Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.